Cytosorbents (NASDAQ:CTSO) Upgraded to “Moderate Buy” at WBB Securities

WBB Securities upgraded shares of Cytosorbents (NASDAQ:CTSO) to a moderate buy rating in a research report sent to investors on Wednesday morning,Zacks reports.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Cytosorbents in a research report on Friday, October 2nd. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Cytosorbents presently has a consensus rating of “Hold” and an average price target of $74.83.

Cytosorbents Trading Up 0.6%

CTSO stock opened at $5.35 on Wednesday. Cytosorbents has a twelve month low of $2.84 and a twelve month high of $17.28. The stock has a market capitalization of $16.86 million, a price-to-earnings ratio of -0.92 and a beta of 1.37. The company has a quick ratio of 0.50, a current ratio of 0.66 and a debt-to-equity ratio of 4.70. The firm’s fifty day simple moving average is $5.61 and its two-hundred day simple moving average is $8.11.

Cytosorbents (NASDAQ:CTSO) last issued its earnings results on Thursday, August 6th. The medical research company reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.80) by $0.73. The business had revenue of $9.63 million for the quarter, compared to the consensus estimate of $9.38 million. Cytosorbents had a negative net margin of 48.94% and a negative return on equity of 431.65%. As a group, analysts anticipate that Cytosorbents will post -4.40 earnings per share for the current year.

Insider Buying and Selling at Cytosorbents

In other Cytosorbents news, CEO Phillip Chan bought 200,000 shares of the company’s stock in a transaction dated Friday, September 4th. The stock was acquired at an average price of $0.35 per share, with a total value of $70,000.00. Following the completion of the acquisition, the chief executive officer directly owned 1,944,432 shares of the company’s stock, valued at $680,551.20. This represents a 11.47% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 7.80% of the stock is currently owned by company insiders.

Cytosorbents Company Profile

CytoSorbents Corporation is a medical device company that develops blood purification technologies designed to remove harmful substances from the bloodstream. Its products use proprietary, porous polymer adsorbent technology to reduce circulating cytokines, inflammatory mediators, toxins and other substances associated with serious illness.

The company’s principal product, CytoSorb, is an extracorporeal blood purification device used in critical care and other clinical settings. It is designed to help manage excessive inflammation and is used with existing blood-pumping systems.